Drug Administration Route Found Obvious

Oct 25, 2016

Reading Time : 1 min

The court considered and rejected the applicant’s expert’s arguments that oral inhalation of zanamivir provided unexpected results. PTAB and the court found that a study presented by the expert did not show unexpectedly superior results and that another study was not persuasive because it dealt with the prevention of influenza, not the treatment of it.

In dissent, Judge Newman argued that the court failed to properly consider the applicant’s expert’s opinion. Specifically, the expert concluded from a large international study that the effectiveness of orally inhaled zanamivir as compared with nasal administration could be considered an unexpected result. Judge Newman also criticized the court’s finding because for a method to be obvious to try in unpredictable arts, such as medicinal treatment, there must be some suggestion in the prior art that the method would have a reasonable likelihood of success. Judge Newman noted that the prior art did not suggest oral inhalation was a method for administration of zanamivir. In addition, Judge Newman found that the court’s statement that inhalation is reasonably understood to include oral inhalation is without authority.

In re: Constantin Efthymiopoulos, Case No. 2016-1003 (Fed. Cir. Oct. 18, 2016).

Share This Insight

Previous Entries

IP Newsflash

November 17,2025

The district of Delaware recently denied a defendant’s partial motion to dismiss pre-suit willful infringement from the litigation, finding instead that the allegations taken as a whole were sufficient to support pre-suit willfulness at the pleading stage. Specifically, the court found that the allegations as to the defendant’s involvement in a related foreign opposition proceeding and participation in the relevant industry were accompanied by detailed factual support that sufficiently pleaded willful infringement for the pre-suit period.

...

Read More

IP Newsflash

November 14, 2025

The Ninth Circuit recently reversed a district court’s decision to strike a plaintiff’s trade secret claims under the Defend Trade Secrets Act (DTSA) at the discovery stage. In doing so, the Ninth Circuit made clear that under the DTSA, whether a party defined their trade secret with sufficient particularity is a question of fact that generally does not lend itself to resolution in the absence of at least some discovery. This ruling contrasts with the California Uniform Trade Secrets Act (CUTSA), which requires a party to define their trade secrets with reasonable particularity before commencing discovery.

...

Read More

IP Newsflash

November 11, 2025

The Federal Circuit recently vacated a summary judgment ruling of invalidity, holding that the district court erred in applying preclusive effect to the Patent Trial and Appeal Board’s unpatentability findings regarding other claims in the same patent. In doing so, the Federal Circuit reiterated that issue preclusion does not apply where the prior factual determinations were made under a lower standard of proof.

...

Read More

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.